PATENT CLAIM ANALYSIS

Application Number: 15953716
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "152100"]

Abstract:
Antibodies to human N3pGlu Aβ, compositions comprising such N3pGlu Aβ antibodies, and methods of using such N3pGlu Aβ antibodies for the treatment of a disease characterized by deposition of Aβ including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.

Claim (Index 23):
A mammalian cell transformed with the DNA molecule of  claim 20 , wherein the transformed cell is capable of expressing an antibody comprising two heavy chains and two light chains, wherein the amino acid sequence of each heavy chain is given by SEQ ID NO: 12 and the amino acid sequence of each light chain is given by SEQ ID NO:13.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 91.0
- Lexical Diversity: 1.52941
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15402268', '13810895', '14039113', '12976282', '12754579']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7272702578231766
- 35 USC 102 Novelty (BERT): 0.5638847673024706
- Combined Prediction Score: 0.710931708771106
- Mean Citation Score: 360.161788
- Max Citation Score: 473.79208
- Similarity Product: 324.188755838809

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test